Recap: Allogene Therapeutics Q4 Earnings
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Allogene Therapeutics Q4 EPS $(0.54) Beats $(0.60) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 1.89 percent decrease over losses of $(0.53) per share from
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
Allogene Therapeutics Earnings Preview
Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement.
Analysts estimate that Allogene Therapeutics will report an earnings per share (EPS) of $-0.60.
FDA Lifts Clinical Hold On Allogene’s CAR-T Trials
The FDA has lifted the hold on Cellectis SA's (NASDAQ:
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal Of FDA Clinical Hold On Their Clinical Trials
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene